PMC:7162774 / 4007-4598
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
139 | 4-11 | Species | denotes | patient | Tax:9606 |
140 | 211-218 | Species | denotes | patient | Tax:9606 |
141 | 481-488 | Species | denotes | patient | Tax:9606 |
142 | 29-47 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
143 | 96-107 | Chemical | denotes | Oseltamivir | MESH:D053139 |
144 | 153-172 | Chemical | denotes | lopinavir-ritonavir | MESH:C558899 |
145 | 235-254 | Chemical | denotes | lopinavir–ritonavir | MESH:C558899 |
146 | 404-422 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
147 | 545-555 | Chemical | denotes | remdesivir | MESH:C000606551 |
148 | 570-580 | Chemical | denotes | creatinine | MESH:D003404 |
149 | 337-355 | Disease | denotes | hyperbilirubinemia | MESH:D006932 |
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T51 | 29-47 | CHEBI:5801;DG_20;CHEBI:5801 | denotes | hydroxychloroquine |
T52 | 96-107 | CHEBI:7798;CHEBI:7798 | denotes | Oseltamivir |
T53 | 153-162 | CHEBI:31781;CHEBI:31781;DG_23 | denotes | lopinavir |
T54 | 163-172 | CHEBI:45409;CHEBI:45409;DG_30 | denotes | ritonavir |
T55 | 235-244 | CHEBI:31781;CHEBI:31781;DG_23 | denotes | lopinavir |
T56 | 245-254 | DG_30 | denotes | ritonavir |
T57 | 404-422 | CHEBI:5801;DG_20;CHEBI:5801 | denotes | hydroxychloroquine |
T58 | 545-555 | DG_28 | denotes | remdesivir |
T59 | 570-580 | CHEBI:16737;CHEBI:16737 | denotes | creatinine |
T56070 | 29-47 | CHEBI:5801;DG_20;CHEBI:5801 | denotes | hydroxychloroquine |
T87166 | 96-107 | CHEBI:7798;CHEBI:7798 | denotes | Oseltamivir |
T36846 | 153-162 | CHEBI:31781;CHEBI:31781;DG_23 | denotes | lopinavir |
T33068 | 163-172 | CHEBI:45409;CHEBI:45409;DG_30 | denotes | ritonavir |
T73640 | 235-244 | CHEBI:31781;CHEBI:31781;DG_23 | denotes | lopinavir |
T95625 | 245-254 | DG_30 | denotes | ritonavir |
T26539 | 404-422 | CHEBI:5801;DG_20;CHEBI:5801 | denotes | hydroxychloroquine |
T42752 | 545-555 | DG_28 | denotes | remdesivir |
T1500 | 570-580 | CHEBI:16737;CHEBI:16737 | denotes | creatinine |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T13 | 396-400 | Body_part | denotes | back | http://purl.org/sig/ont/fma/fma25056 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T35 | 337-355 | Disease | denotes | hyperbilirubinemia | http://purl.obolibrary.org/obo/MONDO_0002408|http://purl.obolibrary.org/obo/MONDO_0024288 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T49 | 454-455 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T50 | 504-505 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T16 | 29-47 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T17 | 96-107 | Chemical | denotes | Oseltamivir | http://purl.obolibrary.org/obo/CHEBI_7798 |
T18 | 153-172 | Chemical | denotes | lopinavir-ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T19 | 153-162 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T20 | 163-172 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T21 | 235-244 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T22 | 245-254 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T23 | 404-422 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T24 | 545-555 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T25 | 570-580 | Chemical | denotes | creatinine | http://purl.obolibrary.org/obo/CHEBI_16737 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T27 | 0-95 | Sentence | denotes | The patient was treated with hydroxychloroquine 600 mg twice daily after the initial diagnosis. |
T28 | 96-375 | Sentence | denotes | Oseltamivir 75 mg twice daily was added and, once liquid lopinavir-ritonavir was available at our institution, the patient was switched to lopinavir–ritonavir 400–100 mg twice daily on treatment day 5, but was discontinued in the setting of hyperbilirubinemia on treatment day 9. |
T29 | 376-476 | Sentence | denotes | He was transitioned back to hydroxychloroquine 200 mg twice daily to complete a total 14-day course. |
T30 | 477-591 | Sentence | denotes | The patient was deemed not a candidate for the compassionate use of remdesivir owing to poor creatinine clearance. |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T33 | 337-355 | Phenotype | denotes | hyperbilirubinemia | http://purl.obolibrary.org/obo/HP_0002904 |